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Abstract
Statins are well-known cholesterol lowering drugs targeting HMG-CoA-reductase, reducing the risk of coronary
disorders and hypercholesterolemia. Statins are also involved in immunomodulation, which might influence the
outcome of bacterial infection. Hence, a possible effect of statin treatment on Listeriosis was explored in mice. Statin
treatment prior to subsequent L. monocytogenes infection strikingly reduced bacterial burden in liver and spleen (up
to 100-fold) and reduced histopathological lesions. Statin-treatment in infected macrophages resulted in increased
IL-12p40 and TNF-α and up to 4-fold reduced bacterial burden within 6 hours post infection, demonstrating a direct
effect of statins on limiting bacterial growth in macrophages. Bacterial uptake was normal investigated in microbeads
and GFP-expressing Listeria experiments by confocal microscopy. However, intracellular membrane-bound
cholesterol level was decreased, as analyzed by cholesterol-dependent filipin staining and cellular lipid extraction.
Mevalonate supplementation restored statin-inhibited cholesterol biosynthesis and reverted bacterial growth in
Listeria monocytogenes but not in listeriolysin O (LLO)-deficient Listeria. Together, these results suggest that statin
pretreatment increases protection against L. monocytogenes infection by reducing membrane cholesterol in
macrophages and thereby preventing effectivity of the cholesterol-dependent LLO-mediated phagosomal escape of
bacteria.
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Introduction
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-CoA), a crucial enzyme in
cholesterol biosynthesis pathway. Clinically, statins are
extensively prescribed drugs to reduce morbidity and mortality
in patients with coronary disorders and hypercholesterolemia
[1]. Of note, it has also been observed that statin treatment can
reduce mortality in patients with active bacteremia [2]. Apart
from the ability of statins to decrease mortality in patients with
cardiovascular diseases or bacteremia, studies have reported
immunomodulatory and inflammatory properties of statins,
independent of their ability to lower cholesterol levels [3,4]. A
protective role for statins has also been observed in other
disease models. Recently, a case study amongst US veterans
showed that statin treatment reduced their risk of lung cancer
[5]. In addition to cancer, statins have been implicated in
controlling Dengue virus replication in human PBMCs [6] and
Epstein–Barr virus (EBV)-induced tumor formation in SCID
mice was reduced following treatment with simvastatin,
resulting in increased survival [7].
Previously, depletion studies using methyl-β-cyclodextrin
(MβCD) have shown cholesterol to be crucial for the uptake of
various pathogens, including viruses [8], protozoan parasites
[9] and bacteria [10,11]. Rapid sequestration of cholesterol by
cyclodextrin promotes conformational changes in the
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membrane and alters lipid rafts, membrane receptors and their
intracellular signalling pathways [12,13], which may explain the
reduced uptake of pathogens. Statins have also been reported
to influence lipid raft-mediated FcγR signalling in human
monocytes [14] and lymphocyte signalling by disrupting lipid
rafts [15]. Moreover, statins influence neuroprotection by
reducing the association of N-methyl-D-aspartate receptors to
lipid rafts [16].
The gram-positive bacterium, Listeria monocytogenes, which
is the causative agent of listeriosis, also exploits cholesterol to
invade macrophages. Recent evidence has shown that survival
of L. monocytogenes in macrophages is dependent on 25-
hydroxycholesterol [17]. In order to reside within macrophages,
L. monocytogenes evades macrophage-mediated killing by
expressing their signature virulence factor, known as
listeriolysin O (LLO). LLO is a cytolysin which binds with
cholesterol to create a membrane pore that allows bacterial
escape into the cytoplasmic space for proliferation and
dissemination into neighboring cells [18]. It is noteworthy to
mention a recent finding on another cholesterol-dependent
cytolysin, pneumolysin, which is secreted by S. pneumoniae.
Here, authors showed that statins have a protective effect on
pneumolysin-mediated host cell lysis and bacterial burden in a
mouse model of sickle cell disease [19]. This therefore
suggests that inhibition of host cholesterol using
pharmaceutical agents, such as statins, could potentially
influence bacterial escape and alter the disease outcome.
While it has been shown that statin treatment can lower
bacterial burdens, during Salmonella enterica [20] and
Chlamydia pneumoniae [21] infections in mice, the mechanism
behind the antimicrobial activity of statins remains inconclusive.
Importantly, statins do not significantly decrease serum
cholesterol levels in mice, as rodents express less number of
LDL receptors than humans which results in decreased uptake
of LDL cholesterol from the blood circulation [22]. More
recently, an intriguing finding revealed that statins target the
outcome of bacterial infection by forming DNA-based
extracellular traps (ETs), an extracellular mechanism
responsible for antimicrobial activity in macrophages/
neutrophils. This finding indicates that statins can target more
than one mechanism in vivo [23].
In the present study, we investigated the effect of statin
treatment on the growth of the intracellular pathogen, L.
monocytogenes both in vivo and in vitro. In summary, we show
that simvastatin increases host defense against listeriosis by
targeting LLO-dependent escape of L. monocytogenes.
Materials and Methods
Mice and bacteria
C57BL/6 mice were maintained under specific-pathogen-free
conditions within the biomedical animal facility of the Health
Sciences Faculty, University of Cape Town. Mice were aged
(8-12 weeks) and sex-matched for each experiment. L.
monocytogenes (EGDe strain) were used for infection [24] and
L. monocytogenes ∆LLO mutant strain and GFP-expressing L.
monocytogenes (BUG2377: EGDe-GFP-Cr) was a gift from T.
Chakraborty (Institute of Medical Microbiology, University of
Giessen, Giessen, Germany) and Edith Gouin (Bacteria cell
interactions, Pasteur institute, Paris, France) respectively.
Ethics statement
All experiments were performed in strict accordance with
South African National Guidelines and University of Cape Town
of practice for laboratory animal procedures. All mouse
experiments were performed according to protocols (Permit
number: 012/037) approved by the Animal Ethics Committee of
the Faculty of Health Sciences, University of Cape Town. All
animal users had successfully completed the mandatory
University of Cape Town animal handling courses. All
procedures were performed under halothane anesthesia and
all efforts were made to minimize suffering.
Simvastatin treatment and Listeria monocytogenes
infection in mice
Mice were administered with the indicated doses of
simvastatin, pravastatin (Sigma-Aldrich) or phosphate buffered
saline (PBS) intraperitoneally daily for one or two weeks as
shown in the layout. Following treatment, mice were infected
intraperitoneally with L. monocytogenes (2x105 CFU) and
sacrificed at day 3 post-infection. Bacterial burden and
histopathology on lungs and spleens was performed as
previously described [24,25].
Macrophage treatment and infection in vitro
Bone marrow-derived macrophages (BMDM) were
generated as described [26] and RAW264.7 murine
macrophage cell line was a gift from Prof. Gordon Brown,
University of Aberdeen, UK. 5x105 cells were cultured in the
presence of indicated concentrations of simvastatin or PBS for
24 hours. Cells were then infected with L. monocytogenes
(MOI=10) or Listeria mutant for LLO (ΔLLO) for 1 hour in the
presence of simvastatin (50 µM) ± mevalonate (100 µM). At the
indicated time points, bacterial growth in cultured cells was
determined as previously described [24].
Cytokine and nitric oxide measurements
Following treatment with simvastatin and IFN-γ (100
Units/ml) overnight, macrophages were infected with L.
monocytogenes and incubated at 37°C for 1 hour. Cytokines
such as IL-12p40, TNF-α and IL-6 in cell culture supernatants
were measured by sandwich ELISA whilst nitric oxide (NO)
was detected by Griess reagent assay [24].
Cholesterol content in macrophages and serum
After statin treatment, macrophages were stained for
cholesterol using filipin dye as previously reported [27].
Alternatively, cholesterol content was measured in soluble
supernatant of total cell lysates using an enzymatic cholesterol
assay kit according to manufacturer’s instructions (Bioassay
system) [28] or in serum using commercial kit (KAT).
Cell viability and cytotoxicity
After statin treatment, cellular viability and cytotoxicity was
measured by reduction of yellow 3-(4,5-dimethythiazol-2-
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yl)-2,5-diphenyl tetrazolium salt (MTT) (Sigma-Aldrich) by
mitochondrial succinate dehydrogenase enzyme of living cells
as previously described [29].
Phagocytosis assay
After statin treatment, macrophages were incubated with
beads (4.5μm, FITC labeled Dynabeads, Invitrogen) at a ratio
of 10:1. After 1 hour of incubation at 37°C, non-adherent beads
were removed by washing with ice-cold PBS and cells were
then fixed in 4% paraformaldehyde [30]. Four random fields
were photographed using Carl Zeiss LSM 510 confocal
microscope. Quantification of internalized beads was based on
more than 100 macrophages per treatment.
Extracellular growth of Listeria in the presence of
simvastatin
Tryptic soy broth (TSB) supplemented with simvastatin at the
indicated concentrations were inoculated with L.
monocytogenes and cultured on an orbital shaker for 24 hours
on 120 rpm at 37°C. Dilutions of cultures were prepared and
plated on tryptic soy agar plates to allow enumeration of
bacterial numbers.
ELISA and Western blot analysis of Listeriolysin O
(LLO) expression by Listeria
L. monocytogenes was diluted (1/10) in TSB containing the
indicated concentrations of simvastatin and grown to OD600 =
0.6. Culture supernatants were analysed for the detection of
LLO by ELISA using rabbit anti-LLO (Abcam) primary antibody
and alkaline phosphatase-conjugated goat anti-rabbit (BD
Bioscience) secondary antibody. Secreted proteins from culture
supernatants were precipitated using 10% ice-cold
trichloroacetic acid [31] and Western blotting was performed
using horseradish peroxidase-conjugated mouse anti-rabbit
(Cell Signalling Technology) as secondary antibody.
Confocal Microscopy
Simvastatin-treated macrophages were infected with GFP-L.
monocytogenes for 1 hour. Following washing with warm
medium to remove extracellular bacteria, cells were fixed at the
indicated time points using 4% paraformaldehyde and
subjected to actin staining using Rhodamine Phalloidin
(Molecular Probes) for 30 minutes at room temperature. Cells
were then mounted in mowiol and images were acquired using
Carl Zeiss LSM 510 confocal microscope.
Statistical analysis
Data is represented as mean values ± SEM. Statistical
analysis was performed using the unpaired Student’s t test,
defining differences to untreated control groups as significant
(*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001) unless otherwise
stated (Prism software).
Results
Host defense against Listeria monocytogenes is
increased by simvastatin treatment in mice
We investigated the effect of simvastatin treatment on
bacterial burden during the acute phase of L. monocytogenes
infection in mice. Intraperitoneal administration of 10 and 20
mg/kg/day of simvastatin (Figure 1A) resulted in a 100-fold
reduction of bacterial burden in the liver and spleen at day 3
post-infection (Figure 1B). This reduction in bacterial burden
was accompanied by well-defined, small hepatic
microabscesses in simvastatin-treated mice as revealed by
liver histopathology and subsequent quantification of lesion
sizes (Figure 1C). Furthermore, L. monocytogenes infection
significantly increased serum cholesterol (Figure 1D) but not
triglycerides (Figure 1E) levels when compared to non-infected
mice. In addition, simvastatin treatment alone has no effect on
the levels of serum cholesterol in mice (Figure 1F).
We next tested pravastatin, a hydrophilic statin. Mice were
treated intraperitoneally with pravastatin at 2 and 10 mg/kg/day
as shown in Figure 2A. Pravastatin treatment showed a trend
towards decreased bacterial loads in the spleen (Figure 2B)
and liver (Figure 2C), when compared to control mice group. At
day 3 post-infection, serum cholesterol levels were significantly
decreased in pravastatin-treated mice when compared to non-
statin treated mice (Figure 2D). The significant reduction in
bacterial burden by simvastatin treatment could be attributed to
the fact that lipophilic statins can cross the plasma membrane
more easily as compared to hydrophilic statins [32]. These
results suggest that simvastatin treatment is able to reduce
bacterial burden and dissemination to the spleen early during
infection with L. monocytogenes in mice.
Simvastatin reduces listerial growth in primary
macrophages and a murine macrophage cell line
(RAW264.7)
To investigate whether statins could potentially reduce the
growth of Listeria at a cellular level, primary murine
macrophages BMDMs (Figure 3A) and the murine macrophage
cell line RAW264.7 (Figure 3B) were treated with different
concentrations of simvastatin overnight and subsequently
infected with L. monocytogenes. At the indicated time points
after infection (Figure 3A, B), growth of L. monocytogenes was
significantly reduced both in BMDMs and RAW264.7
macrophages when treated with 50 µM and above of
simvastatin. To rule out the possibility of simvastatin-mediated
cytotoxicity in cells, we performed MTT assays to assess the
viability of primary macrophages. As shown in Figure 3C, no
major differences in viability were observed at any of the
simvastatin concentrations used. Similarly, simvastatin had no
cytotoxic effect on RAW264.7 macrophages (data not shown).
Together, these results show that simvastatin mediates
intracellular control of L. monocytogenes growth in murine
macrophages.
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Increased IL-12p40 and TNF-α production by
macrophages following simvastatin treatment
Since IL-12 [33,34] or TNF-α [35] have been shown to
reduce bacilli burdens during bacterial infection, We evaluated
if statin treatment also enhanced IL-12p40 and TNF- α
production in BMDMs. Macrophages were treated with
simvastatin and stimulated with IFN-γ for 18 hours and
subsequently infected with L. monocytogenes. By 12 hours
post-infection, simvastatin significantly enhanced the
production of IL-12p40 in a dose-dependent manner (Figure
3D), which was accompanied by a significant increase in TNF-
α (Figure 3E) whilst non-infected macrophages did not show
IL-12p40 and TNF-α production by simvastatin treatment alone
(data not shown). Simvastatin also did not affect IL-6 or nitric
oxide production in infected BMDMs (Figure 3F, G). Similar
results were obtained with RAW264.7 macrophages (data not
Figure 1.  Effect of simvastatin treatment on Listeria monocytogenes infection in mice.  (A) Mice were treated with
simvastatin at 10 and 20 mg/kg/day or with vehicle control by daily intraperitoneal injection for 12 days. Mice were infected
intraperitoneally with L. monocytogenes (2x105 CFU) and sacrificed as indicated in the layout. (B) Bacterial burden in the spleen and
liver determined at 3 days post-infection. Pooled data from two independent experiments are shown. (C) Hematoxylin and eosin
stained liver section to determine lesion size in 50-150 microabscesses/group (Original magnification x200). (D) Cholesterol and (E)
triglyceride levels were measured in sera before and 3 days after L. monocytogenes infection in non-statin treated control mice
group. (F) Serum cholesterol levels were measured before and after infection in control and statin-treated groups. Data are
representative of two independent experiments. Data are expressed as mean ± SEM of 6-12 mice/group, * p < 0.05, ** p < 0.01, ***
p < 0.001 versus control.
doi: 10.1371/journal.pone.0075490.g001
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shown). Altogether, these results suggest that following
simvastatin treatment, the increase in production of pro-
inflammatory cytokines in macrophages could have contributed
to host protection against Listeriosis.
Simvastatin decreases cholesterol levels and has no
effect on phagocytosis in macrophages
To test whether simvastatin decreases membrane host
cholesterol biosynthesis, macrophages were stained with filipin,
a fluorescent dye that specifically binds to cell membrane
cholesterol. Treatment of macrophages with simvastatin
significantly decreased filipin intensity whilst, supplementation
of mevalonate restored filipin intensity (Figure 4A, B). In line
with our previous observations in vivo (Figure 1D), cholesterol
levels in macrophages were significantly increased following L.
monocytogenes infection (Figure 4C). Next, we used lipid
extraction to directly quantify the content of intracellular
cholesterol in macrophage cell lysates. As observed from the
filipin-staining assay, total cholesterol content in simvastatin-
treated macrophages was reduced (Figure 4D). Together,
these results demonstrate that simvastatin is able to decrease
both membrane-bound and intracellular cholesterol in
macrophages.
The reduced levels of membrane-bound cholesterol may
have had an influence on phagocytic uptake, which would
explain the decreased L. monocytogenes bacterial growth
observed in macrophages. This hypothesis was tested by
macrophage internalization studies with latex beads using
confocal microscopy. Internalization of beads within one hour
of incubation was similar in control and simvastatin-treated
macrophages. In addition, we observed reduced uptake of
beads in macrophages-treated with methyl-β-cyclodextrin
(MβCD), which was reversed upon treatment in combination
with cholesterol (Figure 4E). Cytochalasin D, a potent inhibitor
of phagocytosis, served as positive control and inhibited
phagocytosis in macrophages (Figure 4E). Furthermore,
uptake of GFP-expressing L. monocytogenes was not impaired
by simvastatin treatment (Figure 4F). Taken together, these
results suggest that simvastatin has no effect on the phagocytic
capacity of macrophages.
Simvastatin has no effect on extracellular growth of L.
monocytogenes in culture broth medium
We next investigated whether simvastatin has a direct
bactericidal effect on the growth of L. monocytogenes in culture
medium. To test this hypothesis, we measured bacterial growth
in culture medium containing different concentrations of
Figure 2.  Effect of pravastatin treatment on L. monocytogenes infection in mice.  (A) Mice were treated with pravastatin at 2
and 10 mg/kg/day or with vehicle control by daily intraperitoneal injection for 8 days. Mice were infected intraperitoneally with L.
monocytogenes (2x105 CFU) and sacrificed as indicated in the layout. (B) Bacterial burdens in the spleen and (C) liver were
determined at 3 days post-infection. (D) Cholesterol levels were measured in sera at indicated times during the course of
experiment. Data are expressed as mean ± SEM of 5 mice/group, ** p < 0.01 versus control.
doi: 10.1371/journal.pone.0075490.g002
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simvastatin. No differences in bacterial growth were observed
between control and simvastatin-supplemented culture broth
(Figure 4G), indicating that simvastatin at the concentrations
used for this study, has no direct effect on the HMG-CoA
reductase of L. monocytogenes. This result suggests that the
reduced bacterial growth of Listeria observed in macrophages
was not due to a bactericidal effect of simvastatin directly on L.
monocytogenes.
Simvastatin decreases listerial growth in macrophages
by interfering with LLO-dependent escape of L.
monocytogenes
Furthermore, we determine if the effect on bacterial growth
was a consequence of inhibition of the cholesterol biosynthetic
pathway, exogenous mevalonate, a precursor in the
biosynthetic pathway of cholesterol downstream of HMG-CoA
reductase, was added on simvastatin-treated cells in order to
restore cholesterol biosynthesis. Supplementation of
mevalonate completely abrogated the simvastatin-mediated
decrease in bacterial growth (Figure 5A). Listeria secretes a
cholesterol-dependent cytolysin, listeriolysin O (LLO), which is
crucial for its escape into the cytoplasm [36]. Interestingly,
bacterial growth in macrophages infected with a L.
monocytogenes mutant strain lacking listeriolysin O (∆LLO)
was not affected by treatment with either simvastatin or
mevalonate (Figure 5A). To directly determine whether
simvastatin-mediated impaired Listeria growth was due to the
inhibition of bacterial escape from the phagosomes,
macrophages were infected with GFP-expressing L.
monocytogenes (green). Actin staining (red) was then
performed using rhodamine phalloidin to identify cytoplasmic
bacteria (yellow; merge) and actin-forming tails of cytoplasmic
bacteria by confocal microscopy (Figure 5B). Listeria found
escaping into the cytoplasm and acquiring actin tails was
strikingly reduced in simvastatin-treated macrophages when
compared to untreated controls. The possibility that simvastatin
treatment might have a direct effect on LLO could be excluded
since LLO production by Listeria was not affected by
simvastatin treatment, as quantified by ELISA (Figure 5C) and
Western blot analysis (Figure 5D) from Listeria culture
supernatants. Together, these results suggest that simvastatin
provides protection against listeriolysin-mediated cytolysis.
Figure 3.  Growth and cytokine profile following L. monocytogenes infection in murine macrophages after simvastatin
treatment.  (A) Murine BMDM and (B) RAW264.7 murine macrophage cell line were pretreated with the indicated concentrations of
simvastatin, followed by L. monocytogenes infection (MOI=10). Bacterial growth was measured at 6 and 12 hours post-infection. (C)
Macrophages were analyzed for statin-mediated cytotoxicity using MTT assay. Following simvastatin treatment and IFN-γ
stimulation, macrophages were infected for 12 hours and supernatants were analyzed for the production of (D) IL-12p40, (E) TNF-α,
(F) IL-6 and (G) nitric oxide. Results are shown as mean ± SEM of triplicate cultures and are representative of two independent
experiments, * p < 0.05, ** p < 0.01 versus control.
doi: 10.1371/journal.pone.0075490.g003
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Hence, mevalonate-mediated cholesterol biosynthesis plays an
important role in listerial growth within macrophages.
Discussion
In the present study, we report for the first time that statins
induce host protective immunity against L. monocytogenes
infection in mouse model of acute listeriosis. Our results show
that simvastatin therapy reduced bacterial burden and
subsequent dissemination to primary target organs. This
reduction in bacterial titers was accompanied by smaller
microabscesses in the livers of statin-treated mice. These
results are consistent with previous reports which showed that
administration of atorvastatin led to a 2-fold reduction in
Salmonella enterica bacterial burden [20]. Following
internalization by macrophages, recruitment of cholesterol is
increased to Salmonella-containing vacuole (SCV)
membranes, which together protect the bacilli from
phagolysosomal maturation and degradation by inhibiting the
recruitment of Rab proteins [37,38]. Similarly, cholesterol is
Figure 4.  Intracellular cholesterol levels and phagocytosis in macrophages in presence of simvastatin.  (A) Representative
images of simvastatin ± mevalonate-treated macrophages overnight. Cells were washed and then stained with filipin and (B)
fluorescent intensity (arbitrary units) per cell was quantified by Laser Scanning Microscope (LSM) software. Data is shown as
intensity from 50-100 cells/group (Original magnification x100). (C) Macrophage cholesterol levels were measured using filipin
staining 1 hour after L. monocytogenes infection. (D) Cholesterol content was measured in simvastatin-treated macrophage cell
lysates following lipid extraction. (E) Macrophages were treated with either simvastatin ± mevalonate for 24 hours or ± methyl-β-
cyclodextrin (MβCD) or with cholesterol for 2 hours, and then incubated with latex beads at MOI=10 to measure phagocytosis
(Original magnification x100). Cells were then analyzed for number of internalized beads in each setting. (F) Uptake of GFP-
expressing Listeria was measured in simvastatin-treated macrophages at 90 minutes post-infection. (G) Extracellular growth of L.
monocytogenes was determined in tryptic soy broth supplemented with indicated concentrations of simvastatin. Results are shown
as mean ± SEM of triplicates and are representative of two or three independent experiments, * p < 0.05, ** p < 0.01 versus control.
doi: 10.1371/journal.pone.0075490.g004
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exploited by listerial virulence factor listeriolysin O (LLO), which
binds to cholesterol leading to membrane rupture, bacterial
escape and subsequent cell to cell spread [18]. We found that
the cholesterol level was increased in mice and in
macrophages following Listeria infection. This indicates that
Listeria is dependent on the cholesterol pathway, which
probably increases the sensitivity of these cells to establish
infection in host cells. In addition, the lytic activity of LLO in
macrophages is dependent on the enzyme γ-interferon-
inducible lysosomal thiol reductase (GILT or Ifi30) present in
phagosomes [39]. Moreover, the capacity of GILT to activate
haemolysin is not only restricted to LLO, but can also activate
Streptolysin O, which is secreted by Streptococcus pyogenes,
another gram-positive bacterium [39]. Our results show a more
profound reduction in bacterial burden when compared to the
previous study on Salmonella [20], which might be due to the
different statin used, different bacterial disease studied, the
duration of treatment and/or the route of administration.
To understand the possible mechanisms by which statins
inhibit L. monocytogenes growth, we investigated if statins
were able to protect macrophages from a cytolysin, LLO
expressed by L. monocytogenes. LLO is required for bacterial
escape from the vacuole into the cytoplasm to proliferate and
disseminate into neighboring cells via actin comets or tails [40].
We therefore infected macrophages with L. monocytogenes
deficient for LLO (ΔLLO). The growth of ΔLLO was similar in
control and simvastatin-treated macrophages, indicating that
simvastatin prevent LLO-mediated cytolysis when infected with
Figure 5.  Phagosomal escape of L. monocytogenes in macrophages treated with simvastatin.  (A) BMDM were treated
overnight with simvastatin (100 µM) ± mevalonate (100 µM) and infected with either L. monocytogenes or LLO mutant L.
monocytogenes (MOI=10) for 1 hour. After 12 hours, viable bacilli were determined. (B) Representative images showing actin tails
(white arrows) and phagosomal escape (white circles) in simvastatin-treated and control macrophages followed by quantification
during the course of Listeria infection (Scale bar = 10µm). Production of LLO secreted by Listeria in presence of indicated
concentrations of simvastatin measured by (C) ELISA and confirmed by (D) Western blot analysis. Results are shown as mean ±
SEM of triplicate cultures and are representative of two or three independent experiments, * p < 0.05, ** p < 0.01 and *** p < 0.001
versus control.
doi: 10.1371/journal.pone.0075490.g005
Role of Statins against Listeriosis
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75490
wild type L. monocytogenes, and in the absence of LLO, this
protective effect of statin was lost. Furthermore, we showed
that simvastatin treatment reduced the number of Listeria
escaping into the cytoplasm and formation of actin tails was
also reduced. This shows that simvastatin-treated
macrophages were protected against the effects of listeriolysin
O, a major virulence factor of L. monocytogenes. Hence, the
ability of Listeria to proliferate and disseminate from the
cytoplasm was affected in the presence of simvastatin. These
findings suggest that simvastatin treatment in L.
monocytogenes infected macrophages reduced intracellular
cholesterol and the decreased bacterial growth in these cells
was contingent on cholesterol-dependent LLO. Statins
therefore appear to counteract LLO-dependent escape of
bacteria into the cytoplasm. This finding is consistent with a
recent report, which showed that simvastatin treatment on
endothelial cells protected the host cell lysis by pneumolysin, a
cholesterol-dependent cytolysin secreted by Streptococcus
pneumoniae [19].
Simvastatin treatment also significantly enhanced the
secretion of IL-12p40 and TNF-α as L. monocytogenes
infection progressed in macrophages. A previous report also
showed that simvastatin treatment increases production of
LPS-induced pro-inflammatory cytokines in peritoneal
macrophages. The authors further demonstrated that
simvastatin mediated LPS-induced pro-inflammatory cytokine
secretion by inhibiting the prenylation pathway, which is known
to be important for post-translational modifications. It is
therefore possible that upregulation of IL-12p40 following
simvastatin treatment might be due to an inhibition of
prenylated proteins rather than depletion of cholesterol [41].
Collectively, these results suggest that the simvastatin-
mediated reduction of L. monocytogenes growth was partially
dependent on cytokine production. Previous report have shown
that statin treatment decreases MHC-II expression on human
endothelial cells and macrophages and has no effect on
constitutive expression of MHC II in dendritic cells and B
lymphocytes [3]. Similarly, we also observed that simvastatin
treatment suppressed MHC-II expression on IFN-γ-activated
macrophages and this inhibitory effect was reversed by the
addition of exogenous mevalonate. In addition, we found that
simvastatin had no effect on constitutive expression of MHC-II
(data not shown).
Recent studies have also shown that statins inhibit cell
proliferation of various cell types including cancer cells [42,43].
This could be due to cellular efficacy of statins in cell lines that
tends to arrest cell growth. In the present study, we observed a
negligible effect on cell viability and phagocytic capacity of
simvastatin-treated macrophages. Controversially, statins have
been reported to either decrease [44,45] or increase
phagocytosis [46,47]. However, our results suggest that the
statin-mediated reduced bacterial growth was not due to
cytotoxicity or impaired phagocytosis. It is noteworthy to
mention that simvastatin also had no direct effect on the
extracellular growth of L. monocytogenes in broth culture. This
suggests that administration of simvastatin at the
concentrations used in our study was not detrimental to
pathogen uptake and host cell proliferation.
Given the nature of statins such as hydrophilic or lipophilic,
half-life and potency, the outcome may vary in disease
outcome. In the present study, hydrophilic statin (pravastatin)
was not able to significantly lower bacterial burdens in mice
and appears to be less effective then lipophilic statin
(simvastatin). This could be due to three reasons; firstly,
hydrophilic statins crosses the cell membrane primarily through
selective membrane carriers as opposed to passive diffusion.
Secondly, bioavailability of pravastatin is 17% when compared
to simvastatin which is 5%, indicating that simvastatin is readily
absorbed through the membranes. Thirdly, hydrophilic statins
are administered in an active open hydroxy-acid form whereas
lipophilic statins are administered in lactone form, which is then
converted into open hydroxy-acid form by the cells [32]. These
differences in effects of statins might be attributed to
differences in their ability to penetrate the cell membranes.
On the basis of primary structure, sequence alignment and
sensitivity to statins, HMG-CoA reductase enzymes are
classified into Class I and Class II [48]. Eukaryotes utilize class
I HMG-CoA reductase enzymes, which can be inhibited by
statins at lower concentrations. In contrast, class II reductase
enzymes are utilized by prokaryotes and its inhibition requires
1000-fold higher concentrations of statins than compared to
class I enzymes [49]. This could explain the inability of
simvastatin to induce a bactericidal effect on the growth of L.
monocytogenes, which indicates that listerial HMG-CoA
reductase was not affected at the concentrations used in our
study.
In the present study, the maximum dose of simvastatin
administered to mice (20 mg/kg) was higher than that
administered to humans (0.1-1 mg/kg) [50]. Since equivalent
doses in rodents up-regulate the activity of HMG Co-A
reductase by 6- to 10-fold, higher doses are required to induce
adequate inhibition [51]. The administration of high doses in
rodents is warranted since the animals are
pharmacodynamically resistant to the pharmacological effect of
statins. Statins are known not to significantly lower serum
cholesterol levels due to lower levels of low-density lipoproteins
in rodents [20]. Similarly, we observed no change in plasma
cholesterol levels following simvastatin treatment in mice. A
recent report has shown that L. monocytogenes upregulates
expression levels of 25-hydroxycholesterol which increases the
rate of infection in primary macrophages in an IFN-β-
dependent manner. This study further demonstrated that 25-
hydoxycholesterol controls expression of CD5 ligand, which
inhibits activation of caspase-1 thereby promoting survival of L.
monocytogenes in host cells [17]. In agreement with this, we
also observed that serum cholesterol level in mice and
macrophage cholesterol content was increased following
Listeria infection, which possibly promoted the survival of L.
monocytogenes in host cells.
Conclusions
In summary, our findings reveal a beneficial effect of statins
treatment during acute phase of listeriosis. Thus, inhibition of
the host mevalonate pathway by statins can induce protective
immunity against intracellular pathogens by counteracting
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different pathogen-evasion mechanisms. In a separate study,
we have observed a host protective effect of simvastatin in
mice and isolated macrophages infected with Mycobacterium
tuberculosis (manuscript submitted).
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